358 related articles for article (PubMed ID: 34861867)
1. Circulating tumor DNA: a noninvasive biomarker for tracking ovarian cancer.
Yang F; Tang J; Zhao Z; Zhao C; Xiang Y
Reprod Biol Endocrinol; 2021 Dec; 19(1):178. PubMed ID: 34861867
[TBL] [Abstract][Full Text] [Related]
2. Epithelial ovarian cancer and the use of circulating tumor DNA: A systematic review.
Thusgaard CF; Korsholm M; Koldby KM; Kruse TA; Thomassen M; Jochumsen KM
Gynecol Oncol; 2021 Jun; 161(3):884-895. PubMed ID: 33892886
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumor DNA as an early cancer detection tool.
Campos-Carrillo A; Weitzel JN; Sahoo P; Rockne R; Mokhnatkin JV; Murtaza M; Gray SW; Goetz L; Goel A; Schork N; Slavin TP
Pharmacol Ther; 2020 Mar; 207():107458. PubMed ID: 31863816
[TBL] [Abstract][Full Text] [Related]
4. In Silico screening of circulating tumor DNA, circulating microRNAs, and long non-coding RNAs as diagnostic molecular biomarkers in ovarian cancer: A comprehensive meta-analysis.
Zhang L; Hu C; Huang Z; Li Z; Zhang Q; He Y
PLoS One; 2021; 16(4):e0250717. PubMed ID: 33901236
[TBL] [Abstract][Full Text] [Related]
5. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES
Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267
[TBL] [Abstract][Full Text] [Related]
6. Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma.
Kim YM; Lee SW; Lee YJ; Lee HY; Lee JE; Choi EK
J Gynecol Oncol; 2019 May; 30(3):e32. PubMed ID: 30887755
[TBL] [Abstract][Full Text] [Related]
7. Refined characterization of circulating tumor DNA through biological feature integration.
Markus H; Chandrananda D; Moore E; Mouliere F; Morris J; Brenton JD; Smith CG; Rosenfeld N
Sci Rep; 2022 Feb; 12(1):1928. PubMed ID: 35121756
[TBL] [Abstract][Full Text] [Related]
8. Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA.
Giannopoulou L; Kasimir-Bauer S; Lianidou ES
Clin Chem Lab Med; 2018 Jan; 56(2):186-197. PubMed ID: 28753534
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
Cheng F; Su L; Qian C
Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumor DNA in early-stage breast cancer: new directions and potential clinical applications.
Croessmann S; Park BH
Clin Adv Hematol Oncol; 2021 Mar; 19(3):155-161. PubMed ID: 33739964
[TBL] [Abstract][Full Text] [Related]
11. Liquid biopsy of circulating tumor DNA and biosensor applications.
Li X; Ye M; Zhang W; Tan D; Jaffrezic-Renault N; Yang X; Guo Z
Biosens Bioelectron; 2019 Feb; 126():596-607. PubMed ID: 30502682
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumor DNA (ctDNA) in precision oncology of ovarian cancer.
Oikkonen J; Hautaniemi S
Pharmacogenomics; 2019 Dec; 20(18):1251-1253. PubMed ID: 31829836
[No Abstract] [Full Text] [Related]
13. FOXL2 and TERT promoter mutation detection in circulating tumor DNA of adult granulosa cell tumors as biomarker for disease monitoring.
Groeneweg JW; Roze JF; Peters EDJ; Sereno F; Brink AGJ; Paijens ST; Nijman HW; van Meurs HS; van Lonkhuijzen LRCW; Piek JMJ; Lok CAR; Monroe GR; van Haaften GW; Zweemer RP
Gynecol Oncol; 2021 Aug; 162(2):413-420. PubMed ID: 34083028
[TBL] [Abstract][Full Text] [Related]
14. Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer.
Rusan M; Andersen RF; Jakobsen A; Steffensen KD
Eur J Cancer; 2020 Jan; 125():121-129. PubMed ID: 31865042
[TBL] [Abstract][Full Text] [Related]
15. Methylated circulating tumor DNA as a biomarker for colorectal cancer diagnosis, prognosis, and prediction.
Nassar FJ; Msheik ZS; Nasr RR; Temraz SN
Clin Epigenetics; 2021 May; 13(1):111. PubMed ID: 34001239
[TBL] [Abstract][Full Text] [Related]
16. Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review.
Terp SK; Stoico MP; Dybkær K; Pedersen IS
Clin Epigenetics; 2023 Feb; 15(1):24. PubMed ID: 36788585
[TBL] [Abstract][Full Text] [Related]
17. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.
Pereira E; Camacho-Vanegas O; Anand S; Sebra R; Catalina Camacho S; Garnar-Wortzel L; Nair N; Moshier E; Wooten M; Uzilov A; Chen R; Prasad-Hayes M; Zakashansky K; Beddoe AM; Schadt E; Dottino P; Martignetti JA
PLoS One; 2015; 10(12):e0145754. PubMed ID: 26717006
[TBL] [Abstract][Full Text] [Related]
18. Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection.
Fiala C; Diamandis EP
BMC Med; 2018 Oct; 16(1):166. PubMed ID: 30285732
[TBL] [Abstract][Full Text] [Related]
19. The potential of ctDNA analysis in breast cancer.
Tzanikou E; Lianidou E
Crit Rev Clin Lab Sci; 2020 Jan; 57(1):54-72. PubMed ID: 31674269
[TBL] [Abstract][Full Text] [Related]
20. Cell-Free DNA as a Diagnostic Blood-Based Biomarker for Colorectal Cancer: A Systematic Review.
Petit J; Carroll G; Gould T; Pockney P; Dun M; Scott RJ
J Surg Res; 2019 Apr; 236():184-197. PubMed ID: 30694754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
